Community-Based Surveillance of Antimicrobial Use and ...

More documents

Recommendations

Info

4. Mumbai, IndiaFig. 4.6 (A-D): Monthly percentage of prescriptions containing specific ABMs by facility type inphases 1a and 1b (2002 - 2004)Phase 1a (Oct 2002 - Sept 2003) Phase 1b (Oct 2003 -Sept 2004)% prescriptions with ABM3530252015105A1. Cotrimoxazole (2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage% prescriptions with ABM3530252015105A2. Cotrimoxazole (2003-4)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep% prescriptions with ABM252015105B1. Extended-spectrum penicillins(2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage% prescriptions with ABM252015105B2. Extended-spectrum penicillins(2003-4)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep% prescriptions with ABM252015105C1. Fluoroquinolones(2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage% prescriptions with ABM252015105C2. Fluoroquinolones(2003-4)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep% prescriptions with ABM252015105D1. Tetracyclines(2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage% prescriptions with ABM252015105D2. Tetracyclines(2003-4)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverage0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep0Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepError bars indicate CI* Public facility delivering primary health care53
Community-based surveillance of antimicrobial useand resistance in resource-constrained settingsFig. 4.7 (A-D): Monthly use of specific ABM measured as DDDs per 100 patients by facility type inphases 1a and 1b (2002 - 2004)No.DDDs ABM / 100 patients706050403020100A1. Cotrimoxazole (2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepNo.DDDs ABM / 100 patients706050403020100A2. Cotrimoxazole (2003-4)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepNo.DDDs ABM / 100 patients120100806040200B1. Extended-spectrum penicillins(2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepNo.DDDs ABM / 100 patients120100806040200B2. Extended-spectrum penicillins(2003-4)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepNo.DDDs ABM / 100 patients706050403020100C1. Fluoroquinolones (2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepNo.DDDs ABM / 100 patients70605040302010C2. Fluoroquinolones (2003-4)0Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepNo.DDDs ABM / 100 patients160140120100806040200D1. Tetracyclines (2002-3)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug SepNo.DDDs ABM / 100 patients160140120100806040200D2. Tetracyclines (2003-4)Private pharmacyMunicipal dispensary*Private GPHospital OPDAverageOct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep* Public facility delivering primary health careThere appeared to be a much wider monthly variation of ABM use when data wereexpressed as DDDs of ABM per 100 patients, as compared to when expressed as percentageof prescriptions containing at least one ABM. This may be due to the differing availability ofthe concerned ABM, so impacting on doses used, but could also be due to error in datahandling.4.3.3 Effect of ABM on AMRAlthough no associations between AMR and ABM were expected in the short time surveyedin this pilot study, data for both elements are presented in Figure 4.8. The ABM use shown54
Page 2 and 3:
WHO/EMP/MAR/2009.2Community-Based S
Page 4 and 5:
CONTENTSProject members ...........
Page 6:
8.4 Lessons learnt concerning imple
Page 9 and 10:
Community-based surveillance of ant
Page 11:
Page 14 and 15:
How this report is organizedHow thi
Page 16 and 17:
Executive summaryExecutive summaryI
Page 18 and 19: Executive summaryAlthough ABM use a
Page 20 and 21: 1. Background, aims and general met
Page 23 and 24: Community-based surveillance of ant
Page 25: Community-based surveillance of ant
Page 67: Community-based surveillance of ant
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125:
show all

Community-Based Surveillance of Antimicrobial Use and ...

Create successful ePaper yourself

Delete template?

Save as template?